Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

4D Molecular Therapeutics (FDMT) Shares Outstanding (Weighted Average): 2020-2025

Historic Shares Outstanding (Weighted Average) for 4D Molecular Therapeutics (FDMT) over the last 5 years, with Sep 2025 value amounting to $46.7 million.

  • 4D Molecular Therapeutics' Shares Outstanding (Weighted Average) fell 10.14% to $46.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $46.7 million, marking a year-over-year decrease of 10.14%. This contributed to the annual value of $46.2 million for FY2024, which is 8.13% up from last year.
  • Latest data reveals that 4D Molecular Therapeutics reported Shares Outstanding (Weighted Average) of $46.7 million as of Q3 2025, which was up 0.82% from $46.3 million recorded in Q2 2025.
  • Over the past 5 years, 4D Molecular Therapeutics' Shares Outstanding (Weighted Average) peaked at $52.0 million during Q3 2024, and registered a low of $26.7 million during Q1 2021.
  • Over the past 3 years, 4D Molecular Therapeutics' median Shares Outstanding (Weighted Average) value was $46.3 million (recorded in 2025), while the average stood at $44.6 million.
  • Per our database at Business Quant, 4D Molecular Therapeutics' Shares Outstanding (Weighted Average) spiked by 55.45% in 2024 and then decreased by 10.40% in 2025.
  • 4D Molecular Therapeutics' Shares Outstanding (Weighted Average) (Quarterly) stood at $32.1 million in 2021, then increased by 0.79% to $32.4 million in 2022, then spiked by 31.99% to $42.8 million in 2023, then rose by 8.13% to $46.2 million in 2024, then fell by 10.14% to $46.7 million in 2025.
  • Its last three reported values are $46.7 million in Q3 2025, $46.3 million for Q2 2025, and $46.3 million during Q1 2025.